PARAMOUNT trial
PARAMOUNT Trial
The PARAMOUNT Trial (pronounced: /ˈpærəmaʊnt/ trial) is a significant clinical trial in the field of oncology. The term "PARAMOUNT" is an acronym, standing for "Phase III Study of Pemetrexed Maintenance Therapy in Patients with Advanced Non-Small-Cell Lung Cancer".
Etymology
The term "PARAMOUNT" is derived from the phrase "Phase III Study of Pemetrexed Maintenance Therapy in Patients with Advanced Non-Small-Cell Lung Cancer". The trial is named as such due to its focus on the use of Pemetrexed, a chemotherapy drug, as a maintenance therapy for patients with advanced Non-Small-Cell Lung Cancer (NSCLC).
Related Terms
- Pemetrexed: A chemotherapy drug used in the treatment of various types of cancer, including NSCLC. It works by slowing the growth of cancer cells in the body.
- Non-Small-Cell Lung Cancer (NSCLC): A type of lung cancer that is often treated with Pemetrexed. NSCLC is the most common type of lung cancer, accounting for about 85% of all cases.
- Maintenance Therapy: A treatment approach that involves the ongoing use of medication, even after initial treatments such as surgery or chemotherapy have been completed, to help prevent a disease from coming back.
- Phase III Clinical Trial: The third phase in the clinical trial process, during which a new treatment is tested in large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the treatment to be used safely.
See Also
External links
- Medical encyclopedia article on PARAMOUNT trial
- Wikipedia's article - PARAMOUNT trial
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski